Dabrafenib Mesylate
Brand name: Tafinlar
Rank #340 of 500 drugs by total cost
$30.4M
Total Cost
2,377
Total Claims
$30.4M
Total Cost
151
Prescribers
$13K
Cost per Claim
22
Beneficiaries
2,385
30-Day Fills
$202K
Avg Cost/Provider
16
Avg Claims/Provider
About Dabrafenib Mesylate
Dabrafenib Mesylate (sold as Tafinlar) was prescribed 2,377 times by 151 Medicare Part D providers in 2023, costing the program $30.4M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 337 | Tafamidis Meglumine (Vyndaqel) | $31.0M | 1,387 |
| 338 | Midodrine Hcl (Midodrine Hcl) | $30.9M | 383,390 |
| 339 | Sarilumab (Kevzara) | $30.5M | 6,822 |
| 340 | Dabrafenib Mesylate (Tafinlar) | $30.4M | 2,377 |
| 341 | Testosterone (Testosterone) | $30.4M | 131,549 |
| 342 | Hydroxyzine Hcl (Hydroxyzine Hcl) | $30.2M | 1,474,936 |
| 343 | Irbesartan (Irbesartan) | $30.1M | 869,928 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology